Iq-ai Share Discussion Threads

[festario] 25/2/2021 20:57

It's all exciting in theory Spurs.I've thought so for 2 or three years.Then it started to come to fruition.... but then it coincided very bizarrely with some extremely questionable trading and converting by the CEO.If I were him, I would have been converting around 100p, if I genuinely believed that my company was going to get there.

[spurs90] 25/2/2021 20:18

Point 7 of the update from January doesn’t get much discussion which I find odd as it goes into detail about the grant we received (yes we have 2) here it is

7. The Company is fulfilling the work outlined in its two funded grants collaborating with MCW and the Barrow Neurological Institute ("BNI"). Both grants are "industrial-academic partnerships", aimed at commercialising technologies and incorporating them into routine clinical use, and each grant is entering into the second year of its five-year term. The grant in collaboration with MCW is the second such award as part of the Quantitative Imaging Network ("QIN"). The QIN is an initiative sponsored by the US National Cancer Institute ("NCI") promoting research, development, and clinical validation of quantitative imaging tools and methods for the measurement or prediction of tumour response to therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. The grant in collaboration with BNI includes working with major scanner vendors (GE, Siemens, and Philips) to harmonise the way perfusion MRI data is collected and post-processed. The involvement of the major scanner vendors is exciting and very positive, and the Company looks forward to their continued collaboration and support.

Here’s a link to Kathleen Schmainda overall goals of this project



The Quantitative Imaging Network (QIN) promotes research, development and clinical validation of quantitative imaging tools and methods for the measurement or prediction of tumor response to therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Projects include the development and adaptation/implementation of quantitative imaging methods, imaging protocols, and software solutions/tools (used with existing commercial imaging platforms and instrumentation) and application of these methods in current and planned clinical therapy trials. The research projects focus on image-derived quantitative measurements of responses to drugs and/or radiation therapy during clinical trials or standard of care. To achieve the goals of the QIN, multidisciplinary teams which include oncologists as well as clinical and basic imaging scientists are required. The involvement of industrial partners in the development and adaptation/implementation of quantitative imaging methods to aid cancer therapies are encouraged.

The overall goal of this U01 project (CA176110) is to develop and validate both standard and novel perfusion-weighted MRI (PWI) and diffusion-weighted MRI (DWI) biomarkers for evaluation of brain tumors and their response to therapies. Two PWI methods will be characterized for clinical trials. The first more wide-spread DSC (dynamic susceptibility contrast) approach provides tumor rCBV (relative cerebral blood volume) measurements obtained after a pre-load of contrast agent and corrected for confounding contrast agent leakage effects. The second approach, while less-proven has high-potential to become the most comprehensive perfusion solution. It consists of using a spiral perfusion imaging method with consecutive echoes (SPICE), which enables the simultaneous collection of both DSC (dynamic susceptibility contrast) and DCE (dynamic contrast enhanced) perfusion data using only a single dose of contrast agent and incorporates comprehensive correction for leakage effects. In addition, the team will continue to explore the potential of DWI methods for the evaluation of treatment response, specifically by computing changes in the apparent diffusion coefficient (ADC) across time and creating functional diffusion maps (fDM) within non-contrast-agent-enhancing regions.
While both PWI and DWI have demonstrated great promise for treatment monitoring, studies defining their test-retest repeatability, necessary for use of these techniques in clinical trials, are lacking, and thus represent the focus of Aim 1. In addition, early results suggest that hybrid PWI/DWI maps will likely provide the most complete assessment of treatment response, a hypothesis that will be tested in Aim 2. Finally, in order to make the optimized PWI/DWI technology and workflow available in a robust and cost-effective manner for clinical trials and standard practice, Aim 3 involves the development of a commercial integrated image analysis platform for use in large-scale multi-center clinical trials. This aim is being accomplished in collaboration with Imaging Biometrics LLC, co-investigators on the U01.

[sloppyjoe2] 25/2/2021 12:52

You'd think so, wouldn't you?

[festario] 25/2/2021 12:52

Apparently it can!

[greyseal] 25/2/2021 12:42

Oh well...... it can't go on for ever ;o)

[festario] 25/2/2021 12:05

Trevor must still be at his favourite game Greyseal.As, each buy has not budged the price.There is apparently, still ample supply around the 9p level.

[greyseal] 25/2/2021 11:23

I jumped in early doors for 50,000 - every little helps

[festario] 25/2/2021 08:34

A bit of buying needed to test that theory, and I'm maxed out.

[greyseal] 25/2/2021 08:26

I may have got this totally wrong and I am no expert but the 126,000 sell this morning may have been a key trade.

TB's £160,000 o/s CLNs with 9% interest equate to 11,626,666 shares. When he gives instruction to sell there is going to be rounding and so you could quite easily see that he instructed to sell 11,626,000 so that he could cash in the o/s CLNs. It would make a lot of sense that the 126,000 this morning was the final tranche. All very much IMHO.

[sloppyjoe2] 23/2/2021 14:06

Fest - seconded. If TB thinks this company's products have such a bright future, why is he offloading shares as fast as he can?

[greyseal] 23/2/2021 13:49

I am assuming that TB is selling more shares so that he can convert more CLNs.

The latest declaration was 09/12/2020 when he converted £90,000 of the May 2019 CLNs. This leaves him with £160,000 May 2019 CLNs, which converts to 11.6m shares.

I have just added up all of the round number share sells of 100,000 or more and got to around 11m.

If we assume 75% of this sells relate to TB he hopefully only has 2-3m shares to off load, which could be cleared in the next week or so. At which point we should see share price be released. All IMHO

[swan86] 19/2/2021 11:08

Replying to
@TopTradersADVFN
Bayer tweet #IQAI
@IQAI_IB

Bayer AG
@Bayer

hxxp://Leverkusenbayer.com Joined April 2010
2,324 Following
178K Followers

[festario] 19/2/2021 08:26

Some strong buying interest early doors today.

[bigman786] 19/2/2021 07:15

Small world eh. No wonder Trevor Brown is / was selling. He's just pumped 200k into CMH of Walsall, aka Chamberlin & Hill.

[abbynat] 17/2/2021 15:15

this had a nice bit of a rise yesterday, but, i forgot, the TREVOR BROWN connection!

[volsung] 17/2/2021 13:22

Got a few more at 9.4 (that rhymes!)

[master rsi] 16/2/2021 15:59

A bit of profit-taking and the chance to buy it cheaper

Level 2 of 5 v only 1

13:10 CFEP 75,000 9.512:09 JBER 75,000 9.512:13 SCAP 75,000 9.512:11 SING 75,000 9.512:10 WINS 100,000 9.515:12 MREX 75,000 912:43 PEEL 75,000 912:11 STFL 75,000 8.8Offer side10 75,000 MREX 15:1210.25 75,000 STFL 12:1110.5 75,000 JBER 12:0910.5 75,000 SCAP 12:1310.5 75,000 SING 12:1110.5 100,000 WINS 12:1011 75,000 CFEP 13:1011 75,000 PEEL 12:32

[festario] 16/2/2021 13:12

T'uther thread in use.

[the white house] 16/2/2021 12:38

Nah, TB stops selling just prior to his announcing 3 deals in 8 daysStupid, he is not

[glasswala] 16/2/2021 12:35

The seller will all be coming including TB's 100Ks